1. Standards of medical care in diabetes: 2015: summary of revisions. Diabetes Care 2015;38(Suppl):S4.
[CROSSREF] [PMC] [PDF]
2. Ko SH, Kim SR, Kim DJ, Oh SJ, Lee HJ, Shim KH, et al. 2011 Clinical practice guidelines for type 2 diabetes in Korea. Diabetes Metab J 2011;35:431-436.
[CROSSREF] [PUBMED] [PMC]
3. Action to Control Cardiovascular Risk in Diabetes Study Group. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559.
[CROSSREF] [PUBMED] [PMC]
4. McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care 2012;35:1897-1901.
[CROSSREF] [PUBMED] [PMC]
5. Williams SA, Pollack MF, Dibonaventura M. Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2011;91:363-370.
[CROSSREF] [PUBMED]
6. Cryer PE. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes 1994;43:1378-1389.
[CROSSREF] [PUBMED]
7. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;32:1900-1908.
[CROSSREF] [PUBMED] [PDF]
8. Wheeler S, Moore K, Forsberg CW, Riley K, Floyd JS, Smith NL, et al. Mortality among veterans with type 2 diabetes initiating metformin, sulfonylurea or rosiglitazone monotherapy. Diabetologia 2013;56:1934-1943.
[CROSSREF] [PUBMED] [PDF]
9. Oishi M, Yamazaki K, Okuguchi F, Sugimoto H, Kanatsuka A, Kashiwagi A, et al. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32). J Diabetes Investig 2014;5:581-587.
[CROSSREF] [PUBMED]
12. Jeong SU, Kang DG, Lee DH, Lee KW, Lim DM, Kim BJ, et al. Clinical characteristics of type 2 diabetes patients according to family history of diabetes. Korean Diabetes J 2010;34:222-228.
[CROSSREF] [PUBMED] [PMC]
13. Park JY, Lee KU, Kim CH, Kim HK, Hong SK, Park KS, et al. Past and current obesity in Koreans with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1997;35:49-56.
[CROSSREF] [PUBMED]
14. Koo BK, Kim SW, Yi KH, Park KS, Moon MK. Changing relative contribution of abdominal obesity and a family history of diabetes on prevalence of diabetes mellitus in Korean men and women aged 30-49 years from 2001 to 2010. J Diabetes 2015;7:465-472.
[CROSSREF] [PUBMED]
15. Chan WB, Tong PC, Chow CC, So WY, Ng MC, Ma RC, et al. The associations of body mass index, C-peptide and metabolic status in Chinese type 2 diabetic patients. Diabet Med 2004;21:349-353.
[CROSSREF] [PUBMED]
16. Lee WJ, Sobrin L, Lee MJ, Kang MH, Seong M, Cho H. The relationship between diabetic retinopathy and diabetic nephropathy in a population-based study in Korea (KNHANES V-2, 3). Invest Ophthalmol Vis Sci 2014;55:6547-6553.
[CROSSREF] [PUBMED]
17. Rim TH, Byun IH, Kim HS, Lee SY, Yoon JS. Factors associated with diabetic retinopathy and nephropathy screening in Korea: the Third and Fourth Korea National Health and Nutrition Examination Survey (KNHANES III and IV). J Korean Med Sci 2013;28:814-820.
[CROSSREF] [PUBMED] [PMC]
18. Holt RI. Textbook of diabetes; 4th ed. Chichester: Wiley-Blackwell; 2010. p. 460-461.
19. Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT, et al. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008;31:204-209.
[CROSSREF] [PUBMED]